Tel: 88664432
Home > Downloads > Articles

bullet Three Times Weekly Glatiramer Acetate in Relapsing–Remitting Multiple Sclerosis
To assess the efficacy and safety of glatiramer acetate (GA) 40mg administered 33 weekly (tiw) compared with placebo in patients with relapsing–remitting multiple sclerosis (RRMS).
Date: 9/24/2014       (visite count : 6394)
bullet Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis
Mitoxantrone has been approved by the FDA for worsening relapsing remitting and secondary progressive Multiple Sclerosis.
Date: 9/24/2014       (visite count : 9472)
bullet N-acetylcysteine as an adjuvant to clomiphene citrate for successful induction of ovulation in infertile patients with polycystic ovary syndrome
The aim of this study was to evaluate the effect of oral N-acetylcysteine (NAC) administration as an adjuvant to clomiphene citrate (CC) on induction of ovulation outcomes in patients with polycystic ovary syndrome (PCOS).
Date: 9/24/2014       (visite count : 3430)
bullet N-acetyl cysteine for treatment of recurrent unexplained pregnancy loss
Pregnancy could be associated with a state of oxidative stress that could initiate and propagate a cascade of changes that may lead to pregnancy wastage. This process of oxidative stress may be suppressed by the antioxidant effect of N-acetyl cysteine (NAC).
Date: 9/24/2014       (visite count : 3253)
bullet The efficacy of temozolomide for recurrent glioblastoma multiforme
The efficacy of temozolomide (TMZ) in recurrent glioblastoma multiforme (GBM) has been evaluated by several clinical trials. A meta-analysis to assess the overall efficacy of TMZ in the treatment of recurrent GBM was carried out by the authors.
Date: 9/24/2014       (visite count : 3199)
bullet Efficacy of Temozolomide Treatment in Patients with High-grade Glioma
Numerous studies have reported the clinical efficacy of temozolomide (TMZ) treatment for highgrade glioma, but information on Japanese populations has been limited. This study assessed the safety and early outcomes of TMZ treatment, with or without combination therapy.
Date: 9/24/2014       (visite count : 2864)